

SOTAC PHARMACEUTICALS LIMITED

(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GICD - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451



Date: December 24, 2024

To,
The Manager-Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra Kurla Complex, Bandra
(E),
Mumbai - 400 051, Maharashtra, India

Symbol: SOTAC

Sub: Clarification with respect to quick results submitted to the Stock Exchange on Tuesday, October 29, 2024 for the Half year ended on September 30, 2024.

Respected Sir/Madam,

We received a mail from Exchange on December 20, 2024 seeking clarification with respect to quick results submitted on Tuesday, October 29, 2024 for the Half year ended on September 30, 2024 on below mentioned point:

Query: Financial results submitted is not as per format prescribed by SEBI- Disclosure for utilization of issue proceeds for Listed Entities on NSE EMERGE is not attached as per NSE/CML/2024/23 Dated September 05, 2024.

Reply: We would like to clarify that the financial results submitted by the Company are in compliance with the format prescribed by SEBI. All necessary columns, including the corresponding half-year end/previous year-end dates, have been duly included in the financial results, as per the SEBI-prescribed format.

Further, Our Company has already fully utilized the issue proceeds from the IPO for the specific purposes for which the funds were raised, as disclosed in our public offering documents and the Company has already submitted the required Disclosure (Statement of Deviation) for utilization of funds raised through IPO for the Quarter ended June 30th, 2023 to the National Stock Exchange of India Limited as on August 11th, 2023, (Board meeting held on August 11th, 2023 for the approval of financial result as on 30.06.2023) and the web link of the disclosure already submitted is –

https://nsearchives.nseindia.com/corporate/SOTAC_11082023175509_StatementofDeviationSigned.pdf

As per Regulation 32 of SEBI (LODR) Regulations, 2015, and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, along with NSE Circular No. NSE/CML/2024/23 dated September 5, 2024, the submission of the **Disclosure for Utilization of Issue Proceeds is not applicable to our Company as the circular dated September 5th, 2024, clearly states that the certificate shall be submitted until the issue proceeds have been fully utilized or the purpose for which the proceeds were raised has been fulfilled.**

Since our Company has fully utilized the issue proceeds in respect of purpose for which the proceeds were raised as on June 30th, 2023 and necessary disclosures was intimated to Stock Exchange in due time, the said circular is not applicable to our company.

Contact No.: 99135 62852, 87994 83159, 99250 45971



www.sotacpharma.com



sotacpharma@gmail.com

SOTAC PHARMACEUTICALS LIMITED

(Formerly known as, Sotac Pharmaceuticals Private Limited)

Registered Office :

Plot No. PF/21, Nr. Acme Pharma,
Opp. Teva Pharma, Sanand GICD - II,
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

CIN.: L24230GJ2015PLC085451



Kindly take this clarification on your records and oblige us.

Thanking you.

Yours faithfully,

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

Contact No.: 99135 62852, 87994 83159, 99250 45971



www.sotacpharma.com



sotacpharma@gmail.com